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Abstract
Introduction Molecularimagingstrivestovisualiseprocesses
at the molecular and cellular level in vivo. Understanding
these processes supports diagnosis and evaluation of thera-
peutic efficacy on an individual basis and thereby makes
personalised medicine possible.
Apoptosis and molecular imaging Apoptosis is a well-
organised mode of cell suicide that plays a role in cardiovas-
cular diseases (CVD). Apoptosis is associated with loss of
cardiomyocytes following myocardial infarction, atheroscle-
rotic plaque instability, congestive heart failure and allograft
rejection of the transplanted heart. Thus, apoptosis constitutes
an attractive target for molecular imaging of CVD. Our
current knowledge about the molecular players and mecha-
nisms underlying apoptosis offers a rich palette of potential
moleculartargetsformolecularimaging.However,onlyafew
have been successfully developed so far.
Aims This review highlights aspects of the molecular ma-
chinery and biochemistry of apoptosis relevant to the
development of molecular imaging probes. It surveys the role
of apoptosis in four major areas of CVD and portrays the
importance and future perspectives of apoptosis imaging.
The annexin A5 imaging protocol is emphasised since it is
the most advanced protocol to measure apoptosis in both
preclinical and clinical studies.
Keywords Apoptosis.Molecularimaging.
Cardiovasculardisease.AnnexinA5
Apoptosis
The term ‘apoptosis’ is derived from the Greek (apo = from
and ptosis = falling, commonly pronounced ap-a-tow’-sis)
and denotes a regulated process of cell suicide resulting in a
cell corpse that is distinct from the necrotic cell [1, 2].
Whereas necrosis is manifested by cellular swelling, plasma
membrane rupture and rapid release of intracellular con-
stituents into the environment, causing an inflammatory
response [2], apoptosis is characterised by cell shrinkage,
long-lasting maintenance of plasma membrane integrity and
lack of inflammatory responses in the vicinity of the dying
cell [2]. It has long been thought that apoptosis and necrosis
are the only two modes of cell death counterbalancing
mitosis [3]. However, recent insights have taught us that
cells can follow more roads to death than only apoptosis
and necrosis. In 2001, Leist and Jaättelä suggested a model
in which various forms of cell death could be positioned on
a gliding scale between two extremes, apoptosis and
necrosis [4]. The mode of execution depends on the cell
type and the cell death-inducing trigger. Most knowledge
about various modes of cell death has been generated in the
field of oncology, where cell death plays an important role
in the progression and treatment of cancer [5]. Several
intermediate forms of cell death have been identified and
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autophagic cell death. Mitotic catastrophe can be the result
of unsuccessful chromosome segregation, an event that
requires malfunctioning of multiple cell cycle checkpoints.
Catastrophic cells are large and non-viable cells with a
compromised nuclear blueprint leading eventually to cell
death [8]. Mitotic catastrophe appears to be a rare event in
cardiovascular diseases. Autophagic cell death is character-
ised by the total destruction of the cell through autophagy. It
is a process in which cytoplasmic constituents are degraded
through the lysosomal machinery [9]. Autophagic cell death
occurs both in oncology [10, 11] and in cardiovascular
diseases [12]. The various described modes of cell death
differ in morphology and biochemistry [13]. The caspase
cascade is the most remarkable biochemical distinction [14].
It is activated during apoptosis but hardly, or not at all,
during other modes of cell death.
Biochemistry of apoptotic cell death
Two major biochemical routes dominate apoptotic cell
death. They involve the activation of the caspase cascade
through either death-receptor mediated signal transduction
or stress-induced release of cytochrome C from mitochon-
dria [15]. Caspases involved in apoptosis can be grouped
into initiator (caspases 8 and 9) and effector caspases
(caspases 3 and 7). The principal event of the caspase
cascade is the activation of an inactive procaspase into a
proteolytically active caspase. Activation of initiator caspases
occurs through auto-activation, catalysed by the interaction
with ligated death receptors (procaspase 8) or cytochrome
C-containing apoptosome (procaspase 9). Effector caspases
are activated through intra-chain cleavage by active initiator
caspases [16]. In both cases, activation results in the exposure
of active sites that selectively cleave peptide bonds after an
aspartate residue in caspase substrates.
Several checks and balances exist that control burst of
the caspase cascade if triggered by minor undesired
initiating events. Inhibitors of apoptotic proteins (IAPs)
suppress proteolytic activity by binding to activated
caspases. Inhibition of IAPs is in turn required to allow
execution of apoptosis. Smac/DIABLO residing in the
mitochondria and co-released with cytochrome C inhibits
IAPs and permits propagation and amplification of the
proteolytic signal through the caspase cascade. Anti-
apoptotic members of the Bcl-2 family such as Bcl-2 and
Bcl-X prevent the release of cytochrome C and Smac/
DIABLO from mitochondria. Pro-apoptotic members such
as Bax and tBid, which is the result of Bid cleavage by
activated caspase 8, neutralise the protective effects of the
anti-apoptotic members and provoke mitochondria to
release their pro-apoptotic cargo.
The intricate scheme of the apoptotic machinery offers
several potential targets for molecular imaging. For exam-
ple, knowledge about the mechanism of caspase activation
has triggered the design of several strategies to measure
apoptosis [17–19]. The hurdle these methods have to take is
entrance of the reporter of caspase activity into the cell.
Consequently, in vivo applications of such strategies face
unfavourable biodistribution profiles and high background
levels. Targets embedded in the plasma membrane encom-
pass a more promising set of molecules for molecular
imaging.
Phosphatidylserine
An essential part of the apoptotic program consists of the
appearance of ‘eat me’ flags at the cell surface. Phagocytes
recognise these flags and respond by engulfing the dying
cell before it leaks pro-inflammatory components into the
surrounding tissue. The ‘eat me’ flags are, alone or in
combination, specific for the dying cell, allowing phago-
cytes to make the right choice in an environment filled with
living cells.
In 1992, Valerie Fadok and co-workers reported that
phosphatidylserine (PS) becomes exposed on the surface of
apoptotic lymphocytes, where it functions as an ‘eat me’
signal for phagocytes [20]. PS, a negatively charged
aminophospholipid, is predominantly found in the cytofa-
cial membrane leaflets of living cells. The exofacial plasma
membrane leaflet contains predominantly phosphatidylcho-
line and sphingomyelin while PS is almost completely
lacking. The PS asymmetry results from the ATP-dependent
action of the aminophospholipid translocase that transports
PS from the outer to the inner leaflet [21, 22]. During
apoptosis the aminophospholipid translocase is inhibited
and concomitantly a scramblase is activated. The combined
action results in the surface expression of PS whilst the
plasma membrane integrity remains intact.
Surface-expressed PS provides an attractive target for
molecular imaging of apoptosis.
Annexin A5
In the past decade, a molecular imaging protocol was
established to detect and measure apoptosis in vitro and in
vivo in animal models and patients [23–26]. This molecular
imaging protocol is based upon the protein annexin A5
(Anx A5), which binds with high selectivity and with great
affinity (Ka=7nM)[ 27, 28] to the PS abnormally expressed
on the cell membrane of apoptotic cells [21, 22, 29]. Anx
A5 is a member of a multiprotein family of more than 160
proteins that share the property of Ca
2+-dependent binding
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biophysical, biochemical and biological properties of Anx
A5 and other members of the annexin family have been
extensively described in a number of excellent reviews
[30–34].
Detecting apoptosis with Anx A5
The development of annexin-based detection of apoptosis
started in 1992 when Fadok et al. revealed that PS is
expressed on the cell surface of apoptotic cells [35]. This
revelation led Koopman et al. to the design of an apoptosis
detection assay on the basis of fluorescence (fluorescein
isothiocyanate)-labelled Anx A5 [29]. This Anx A5 affinity
assay was further developed by labelling Anx A5 with
biotin or with several radionuclides to facilitate various
protocols for measuring apoptosis both in vitro [36] and in
vivo [23–25, 37–41] in animal models. The availability of
99mTc-labelled Anx A5 produced under GMP regulations
led to the first studies of non-invasive detection of
apoptosis in patients [26, 42–46].
Detection of apoptosis using alternative methods
In addition to Anx A5, several other proteins may have a
high specificity and tight binding to PS. If labelled with a
fluorescent or nuclear probe, these proteins could possibly
be used for in vivo detection of apoptotic cells in the field
of cardiovascular disease and in other disciplines. In
addition, other steps in the apoptotic signalling cascade,
such as the activation of caspase-3, can be utilised to
visualise activation of the apoptotic machinery (Fig. 1).
Synaptotagmin I
One such PS binding protein is the C2 domain of
synaptotagmin I, which binds to anionic phospholipids in
cell membranes [47]. By conjugation of the C2 domain,
synaptotagmin can be used for in vivo molecular imaging
of apoptosis. Zhao and co-workers conjugated the C2
domain with superparamagnetic iron oxide (SPIO) par-
ticles, a very effective T2 relaxing MRI contrast agent, and
injected the product in tumour-bearing mice. They revealed
that a murine lymphoma (EL4) tumour model treated with
cyclophosphamide and etoposide showed an increase in
apoptotic cells from a basal value of 4% to 32% during
chemotherapy. This was readily detected with C2-labelled
SPIO particles and T2W MRI. Tumour regions with the
greatest MRI changes correlated with regions having the
highest proportion of apoptotic and necrotic cells [47].
More recently, the same group labelled the C2A domain of
synaptotagmin I radioactively (
99mT c )o rf l u o r e s c e n t l y
(FITC) and used the labelled synaptotagmin in a reperfused
acute myocardial infarction model (AMI) rat model. They
found both ex vivo and in vivo accumulation of the
radiotracer in the area at risk. Although some of the uptake
was caused by passive leakage due to elevated vascular
permeability in the area at risk, the majority was caused by
specific binding to PS [48].
Both Anx A5 and synaptotagmin I detect apoptotic cells
by selective binding to externalised PS. An alternative
method to detect apoptosis may be to use a target more
upstream in the apoptotic cascade, the effector caspases.
5-Pyrrolidinylsulphonyl isatins
In one study the peptide-based irreversible pan-caspase
inhibitor Z-VAD-fmk was radio-iodinated and suggested as
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Fig. 1 Targets for apoptosis
detection. During apoptosis, initi-
ator caspases are activated, via
either cell death receptor-mediated
or mitochondrial signalling. These
initiator caspases, in turn, trigger
the activation of effector caspases,
such as caspase-3. The activation
of caspase-3 results in the typical
characteristics of apoptosis, such
as DNA fragmentation, substrate
cleavage of cytoplasmic proteins
and cell membrane alterations.
These apoptotic characteristics
and the activation of caspase-3
offer targets for molecular
imaging of apoptosis
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permeability, intracellular targeting of activated caspases
was limited, preventing in vivo application [49]. In more
recent work, non-peptidyl caspase inhibitors of the 5-
pyrrolidinylsulphonyl isatin-type were proposed instead of
a peptide-based caspase, such as Z-VAD-fmk. These
caspase binding radioligands (CBRs) may be capable of
directly targeting apoptosis in vivo. CBRs are expected to
form intracellular enzyme inhibitor complexes by means of
binding to the activated caspases. Kopka and co-workers
succeeded in labelling several 5-pyrrolidinylsulphonyl
isatins with iodine-125 [50]. However, none of these
compounds have been used for non-invasive imaging in
patients yet.
ApoSense
The ApoSense family is a group of low molecular weight
amphipathic apoptosis markers targeting the cell membrane
of apoptotic cells. ApoSense was developed by the Israel-
based company NST. ApoSense has been used in vitro and
in vivo in several disease models associated with cell death,
such as radiation-induced lymphoma, renal ischaemia/
reperfusion and cerebral stroke [51, 52]. However, it is
still not known to which cell membrane target ApoSense
exactly binds. Therefore, it remains a challenge to link
ApoSense binding to the signalling cascades in apoptosis
signalling.
Role and detection of apoptosis in CVD
Apoptosis of cardiomyocytes after myocardial infarction
Several forms of cell death have been observed in the
infarcted myocardium. The central ischaemic zone is
dominated by necrotic cell death, whereas in the periphery
of the area at risk mainly apoptotic cell death is observed.
Apoptotic cell death in the infarct periphery is not the
exclusive domain of the cardiomyocyte. Also non-myocytes,
including endothelial cells, macrophages and blood cells,
contribute to a comparable degree to apoptotic cell death
[53]. Since the process of cell death can be pharmaceuti-
cally manipulated, thereby limiting the extent of myocardial
cell loss, detection and quantification of apoptotic cells are
of importance for determination of the full extent of
reversible myocardial damage. Once the apoptotic program
is activated, several targets are present both for imaging
apoptosis and for therapeutic interventions.
As described earlier, the C2A domain of synaptotagmin I
binds to the exposed PS on apoptotic cells. Zhao and co-
workers developed a radiotracer for PS expression by
labelling synaptotagmin via 2-iminothiolane thiolation with
99mTc, forming a technetium C2A glutathione S-transferase
complex (
99mTc-C2A-GST) [48]. In vivo planar imaging of
AMI in rats was performed on a gamma camera using a
parallel-hole collimator. The uptake of
99mTc-C2A-GST
within the area at risk was quantified by direct gamma
counting. The foremost finding was that in seven of seven
rats the infarct was clearly identifiable as focal uptake in
planar images. This and other findings led the authors to
conclude that the C2A domain of synaptotagmin I labelled
with a radioisotope binds to both apoptotic and necrotic
cells. Ex vivo and in vivo data indicate that, because of
elevated vascular permeability, both specific binding and
passive leakage contribute to the accumulation of the
radiotracer in the area at risk. However, the latter
component alone is insufficient to achieve detectable
target-to-background ratios using in vivo planar imaging.
Annexin A5 has been more widely used to target PS
exposure. Hiller and co-workers [54] recently reported on a
new Anx A5-based T1 contrast agent. They linked Anx A5
to gadolinium diethylenetriamine penta-acetate (Gd-
DTPA)-coated liposomes. In their model of perfused
isolated rat heart, ligation of the left coronary artery for
30 min was followed by reperfusion. T1 and T2* images
were acquired using an 11.7-T magnet before and after
intracoronary injection of the contrast agent. A significant
increase in signal intensity, visible in those regions
containing cardiomyocytes in the early stage of apoptosis,
was found. The group of Weissleder also reported on Anx
A5-based MRI contrast agents [55], demonstrating the
construction of a magneto-optical nanoparticle AnxCLIO-
Cy5.5, which was tested in a murine model of transient
coronary artery (LAD) occlusion. The synthesis of the
probe was achieved in three steps. First, the amino-CLIO
nanoparticle was labelled with Cy5.5 and activated with
SPDP [N-succinimidyl 3-(2-pyridyldithio)propionate], to
yield a compound termed 2PySS-CLIO-Cy5.5. Second,
A n xA 5w a sr e a c t e dw i t hS A T A( N-succinimidyl S-
acetylthioacetate). In the final step of the process, SATAy-
lated Anx A5 was linked with 2PySS-CLIO-Cy5.5 to yield
the multimodal AnxCLIO-Cy5.5 nanoparticle. It was
demonstrated that it is feasible to obtain high-resolution
MR images of cardiomyocyte apoptosis in vivo with the
use of the nanoparticle AnxCLIO-Cy5.5.
In early work preformed by our group a fluorescent
invasive Anx A5-based imaging protocol for myocardial
apoptosis was developed in mice [25]. The promising
findings of this study encouraged use of modified human
recombinant Anx A5 to construct (Anx A5)-n-1-imono-
4-mercaptobutyl, labelled with pertechnetate for clinical
studies. One milligram of
99mTc-Anx A5 (584 MBq) was
injected intravenously 2 h after reperfusion in seven AMI
patients. In six of the seven patients, increased uptake of
99mTc-Anx A5 was seen in the infarcted region of the heart
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images. No uptake was seen in the heart outside the
infarcted area. In all individuals with increased uptake, a
matching perfusion defect (on MIBI SPECT) was observed
(Figs. 2, 3). These results demonstrated the feasibility of
non-invasive monitoring of apoptosis in patients. These
techniques may allow measurement not only of the extent
of reversible damage but also of the efficacy of novel
therapies targeting apoptosis.
Atherosclerotic lesions and plaque instability
Extensive histopathological studies and investigations on
the initiation of atherosclerosis in transgenic mice have
generated a quite detailed picture of the development of
atherosclerosis in the various stages of disease [56–63]. The
onset of plaque formation is characterised by circulating
levels of oxidised low-density lipoproteins, which are
capable of penetrating the endothelial border while inflict-
ing oxidative damage on the endothelial cells in the
process. Subsequently, the reactionary expression of in-
flammatory markers on the endothelial cell surface attracts
circulating monocytes to the site of injury, which, upon
arrival at the scene, differentiate into macrophages and start
ingesting the available lipid and other oxidised particles.
Uninhibited intracellular lipid accumulation compromises
the function of macrophages and converts them into foam
cells [64]. The accompanying secretion of pro-inflammatory
cytokines and matrix-metalloproteinases (MMP) likely con-
tributes to the hostility of the plaque environment and
weakening of collagen matrix structures, both indirectly
through loss of smooth muscle cells and directly through
MMP activity [65]. At a certain point, excess damage to
macrophages and smooth muscle cells induces apoptosis,
causing remnants of lipid-laden dead cells to form small
extracellular lipid droplets.
A luxating moment in atherogenesis is thought to occur
when the remaining population of functional phagocytes
becomes unable to engulf all apoptotic remnants of dying
cells in the environment [65]. Once the lesion contains a
large, necrotic, lipid pool that is covered by a fibrous cap,
primarily consisting of SMCs and extracellular matrix, it is
named an atheroma.
A critical finding for vascular risk prediction is that
although plaque rupture generally requires progression of
lesion size, acute events resulting from rupture may just as
Fig. 2 Transverse tomographic
images in a patient with acute
anteroseptal infarction. a Arrow
shows increased
99mTc-labelled
Anx A5 uptake in the antero-
septal region 22 h after reperfu-
sion. b Perfusion scintigraphy
with sestamibi 6–8 weeks after
discharge shows an irreversible
perfusion defect which coin-
cides with the area of increased
99mTc-labelled Anx A5 uptake
(arrow). L liver. Reprinted with
permission from Elsevier (The
Lancet, 2000, 356, 211)
Fig. 3 Transverse tomographic
images in a patient with acute
anterior wall myocardial infarc-
tion. a Arrow shows increased
uptake of
99mTc-labelled Anx
A5 in the infarct area 17.5 h after
reperfusion. L liver. b Perfusion
defect on sestamibi perfusion
scintigraphy 6–8 weeks after
discharge matches the uptake of
Anx A5 (arrow). Reprinted with
permission from Elsevier (The
Lancet, 2000, 356, 211)
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Coronary catheterisation studies in patients admitted with
acute coronary syndromes have shown that most of the
culprit lesions are below the 50% stenosis threshold [67–
69]. In reality, the extent of the lesion may be under-
estimated, since conventional coronary catheterisation does
not take the extent of outward remodelling of the coronary
artery at the site of atherosclerotic lesions into account. The
emerging cardiac multislice CT technology may be better
equipped to take outward remodelling into account and to
assess the total coronary plaque burden in patients.
Nevertheless, these data imply that though plaque dimen-
sions will in general be sufficient for imaging-target
visualisation, focussing on mere plaque size entails unsat-
isfactory prognostic information for clinical use. From a
biological perspective, several inflammatory parameters are
associated with vulnerable lesions, such as elevated
extracellular levels of MMP and pro-inflammatory cyto-
kines, including a variety of interleukins and chemotactic
proteins, as has been shown in both experimental and
clinical studies [70–73]. Moreover, high-risk lesions are
notorious for displaying high levels of inflammation and
apoptotic cells; in particular, large amounts of apoptotic
macrophages have been found to reside in fragile and
ruptured fibrous caps [59, 65, 74]. In 2000, Kolodgie et al.
[59] examined 40 culprit lesions from cases of sudden
coronary death and reported apoptotic macrophages to
constitute up to 50% of the total macrophage population,
preferentially localising at the site of rupture. Also, once
atheromas have formed, plaques have been found to be far
more sensitive to SMC death than regular arterial walls, as
recently demonstrated by the group of Bennett [61]. Since
all these features share their relation to inflammation and
more specifically apoptosis, detection of apoptosis in vivo
seems a sensible approach to vulnerable plaque identifica-
tion. This approach builds on the pivotal role that apoptosis
plays in promoting plaque progression and disruption;
however, the underlying mechanism is a complex interplay
in which apoptosis affects endothelial cells, smooth muscle
cells and macrophages in a different manner and with
different consequences.
Given the firmly established direct causal relationship
between apoptosis and lesion instability [59, 75], in vivo
visualisation of the apoptotic plaque status could represent
a significant leap forward in the field of therapeutic
management for individual patients (Fig. 4).
The expanding knowledge about plaque biology has led
to the identification of a variety of potentially suitable
molecular markers for vulnerable plaque imaging [76].
S t u d i e sh a v eb e e nr e p o r t e do nt h et a r g e t i n go fs e v e r a l
inflammation-related molecular targets, including vascular
adhesion molecules (ICAM1, VCAM1, E-selectin), neo-
angiogenesis molecules (αvβ3 integrin), scavenger receptors
on macrophages, MMP proteolytic activity, macrophage
metabolic activity and apoptosis (PS) [60, 62, 75–83].
Although some of these approaches have yielded promising
experimental data, there is still a paucity of clinical studies
confirming the feasibility of these targeted approaches in
humans.
Of the clinical results available, the most impressive
have been achieved using
99mTc-Anx A5 SPECT imaging
and [
18F]fluorodeoxyglucose (
18FDG) positron emission
tomography (PET) imaging. The latter has been used for
many years to detect metabolically hyperactive processes in
nuclear oncology. Since the glucose analogue
18FDG is a
marker for foci of increased metabolic activity [84] and it is
known that macrophages involved in atherosclerotic
plaques have a high metabolic rate, there is sound logic
behind this strategy. In addition,
18FDG imaging capitalises
on the merits of oncological medicine since
18FDG is a
Fig. 4 Feasibility of non-invasive imaging of apoptosis by radio-
labelled Anx A5. Left lateral oblique gamma images of experimental
atherosclerotic (a–c) and control (d–f) rabbits injected with
99mTc-Anx
A5; L and K indicate liver and kidney activities, respectively. Images
at the time of injection (a, d) and at 2 h after injection (b, e) are
shown. Although blood pool activity is seen at the time of injection
(a) in the atherosclerotic animal, tracer uptake is clearly visible in the
abdominal aorta (with lesions) at 2 h (b). c Ex vivo image of b shows
intense
99mTc-Anx A5 uptake in the arch and abdominal region.
Annexin-positive areas were confirmed to contain macrophage- and
apoptosis-rich regions in the atherosclerotic plaque by histology. d–f
show the corresponding images in the control animal. Note that the
aorta is indistinguishable from background at 2 h after injection (e).
The blood pool at the time of injection in the control animal (d)i s
comparable to that in the atherosclerotic animal. f Ex vivo aortic
image of the control animal demonstrates the absence of
99mTc-
labelled Anx A5 uptake. From Kolodgie et al. [75]
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sensitivity and accuracy by PET technology, whereas PET
conjugates for most alternative plaque imaging targets are
still in the process of development.
18FDG imaging of
arterial inflammation has been performed with rather
promising results in retrospective studies of oncological
18FDG scans, in experimental settings and in in vivo
clinical studies by Rudd and colleagues [76, 82, 85, 86]. In
an eight-patient pilot study, they were able to correlate
18FDG uptake in carotid lesions of patients scheduled for
endarterectomy with histologically assessed macrophage
density (p<0.005). However, a practical difficulty of
performing
18FDG imaging in the search for coronary
lesion instability lies in the physical activity of the cardiac
muscle, which results in high glucose requirements and
thus severe background signal.
In addition to detection of the vulnerable plaque with
18FDG, imaging of the vulnerable plaque with
99mTc-Anx
A5 has yielded some exciting results as well. The first
demonstration of the feasibility of in vivo imaging of
plaque instability with
99mTc-Anx A5, in animals, was
given in 2003 by Kolodgie et al. It was demonstrated in a
rabbit model of aortic de-endothelialisation followed by a
high-fat diet that
99mTc-Anx A5 showed a ninefold higher
binding to the atherosclerotic vessels than to the control
vessels [75]. Further validation of the Anx A5 imaging
concept in the vulnerable plaque was done by Johnson and
colleagues in 2005 [87]. In a porcine model of atheroscle-
rosis the feasibility of SPECT imaging with
99mTc-Anx A5
to assess atheroma progression in coronary arteries was
demonstrated. This was ultimately challenging owing to the
low mass of the imaging target and cardiopulmonary
motion. As swine and human hearts have similar cardiac
dimensions, these results indicate that non-invasive func-
tional imaging of coronary plaque instability could be
realistic in the near future. The first clinical demonstration
of the feasibility of nuclear vulnerable plaque imaging with
99mTc-Anx A5 was given by Kietselaer et al. in 2004 [43].
In a pilot study, four patients were included who were
scheduled for carotid endarterectomy and had a history of
recent (n=2) or remote (n=2) transient ischaemic attack
(TIA). Before surgery
99mTc-Anx A5 was administered and
SPECT imaging was performed. In the two patients who
had suffered a TIA more than 3 months before imaging and
had since been treated with statins and antiplatelet agents,
no tracer uptake of Anx A5 was observed (Fig. 5).
Histological analysis confirmed stable lesions with negligi-
ble macrophage infiltration and intra-plaque haemorrhage.
In contrast, the two patients who had experienced transient
ischaemia shortly before imaging (3 and 4 days, respec-
tively) demonstrated marked uptake of Anx A5 in the
culprit carotid vessel, while the contralateral arteries
remained clear of tracer binding. Anx A5 binding was
histologically localised to apoptotic macrophage mem-
branes. An interesting finding during this study was that
echo-Doppler examination in one of the patients with a
recent TIA identified a severe stenotic lesion in the
contralateral carotid artery prior to imaging. On the
99mTc-
Anx A5 scan, however, the lesion was negative, though it
might have been suspected as the culprit lesion by
conventional techniques. This finding underlines the poten-
tial added value of functional versus anatomical imaging in
predicting the likelihood of future thrombotic events.
Among the discussed imaging modalities for vulnerable
plaque detection, nuclear imaging (PET in particular) is far
superior to MRI, being capable of detecting probes at the
picomolar range [88]. PET further outperforms SPECT
imaging regarding spatial resolution, with 4- to 6-mm
versus 10- to 15-mm resolution in the centre of the field.
The major difficulty in evaluating PET or SPECT usually
originates from orientation and localisation of the measured
signal in the body. To overcome this, nuclear imaging
modalities can be co-registered and overlaid with conven-
tional CT or MRI imaging, hence providing anatomical
landmarks in relation to molecular information. Improve-
Fig. 5 Images of unstable atherosclerotic carotid artery lesions
obtained with radiolabelled Anx A5. a Transverse and coronal views
obtained by SPECT in patient 1, who had a left-sided TIA 3 days
before imaging. Although this patient had clinically significant
stenosis of both carotid arteries, uptake of radiolabelled Anx A5 is
evident only in the culprit lesion (arrows). b Histopathological
analysis of an endarterectomy specimen from patient 1 (polyclonal
rabbit anti-Anx A5 antibody, ×400) shows substantial infiltration of
macrophages into the neointima, with extensive binding of Anx A5
(brown). c In contrast, SPECT images of patient 3, who had had a
right-sided TIA 3 months before imaging, do not show evidence of
Anx A5 uptake in the carotid artery region on either side. Doppler
ultrasonography revealed a clinically significant obstructive lesion on
the affected side. d Histopathological analysis of an endarterectomy
specimen from patient 3 (polyclonal rabbit anti-Anx A5 antibody,
×400) shows a lesion rich in smooth muscle cells, with negligible
binding of Anx A5. ANT anterior, L left. Copyright © 2004
Massachusetts Medical Society. All rights reserved. [43]
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imaging devices will therefore imply great advantages.
Given the high costs of imaging, diagnostic algorithms in
the future most likely will combine relatively cheap serum
biomarkers that indicate plaque instability with the subse-
quent use of expensive imaging technology in selected
cases. This indicates that the specific niche for both serum
and imaging biomarkers needs to be defined in large
prospective studies. In addition, much is to be gained from
refinements of the radioligand with regard to blood
clearance and biodistribution, since molecular imaging
typically requires fast binding of the probe to the target,
rapid subsequent clearance from the blood and not too short
radioactive half-lives.
Fig. 6 Dual-isotope imaging using 201Tl for left ventricular contour
detection and, simultaneously, radiolabeled annexin A5 in patients
with dilated cardiomyopathy. a Dilated cardiomyopathy patient with
rapid deterioration of left ventricular function. Note focal uptake in
apex and lateral wall, and slight septal uptake. b Dilated cardiomy-
opathy patient in acute heart failure. Note global uptake of radio-
labeled annexin A5. c Dilated cardiomyopathy patient in stable
clinical condition. Uptake is absent even when image is enhanced to
the extent that background radioactivity can be observed. d Family
member of patient in panel b. No clinical evidence is seen of dilated
cardiomyopathy. Note absence of uptake of radiolabeled annexin A5.
ANT, anterior; INF, inferior; LAT, lateral; SEPT, septal. Reprinted by
permission of the Society of Nuclear Medicine from [90]
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Heart failure (HF) is growing to epidemic proportions,
partially due to the better treatment of AMI. The pathogen-
esis of heart failure is still poorly understood. There may be
an important role for cell death in the progression of
congestive HF. A number of papers have reported on the
differences in the amount of cell death in healthy and
failing hearts. The baseline rate of apoptosis in healthy
human hearts is around one to ten cardiac myocytes per 10
5
nuclei. On the other hand, 80–250 heart muscle cells per
10
5 cardiac nuclei undergo apoptosis at any given time in
late-stage dilated cardiomyopathy. However, it remains
unclear whether this cell death is a coincidental finding, a
protective process or a causal component in the pathogen-
esis. In work done by Wencker and co-workers, the
uncertainty of the role of cell death was addressed. In a
transgenic mouse model with a conditionally active caspase
expressed exclusively in the myocardium, they demonstrat-
ed that even very low levels of cardiomyocyte apoptosis
(23 per 10
5 nuclei, compared with 1.5 per 10
5 nuclei in
controls) caused a lethal dilated cardiomyopathy. Inhibition
of this active caspase largely prevented the development of
cardiac dilation and contractile dysfunction. These and
other data suggest that cardiomyocyte apoptosis and
necrosis may be a causal mechanism of heart failure,
contributing to adverse left ventricle (LV) remodelling.
Inhibition of this cell death process may constitute the basis
for novel therapies. Consequently, anti-apoptotic agents
have been developed and tested in animal models of HF
with promising results [89].
Although, as discussed earlier, it is possible to detect cell
death in MI leading to HF, the small amount of cell death
present in heart failure (80–250 cardiomyocytes per 10
5
cardiac nuclei) makes detection with the current techniques
very challenging. However, the feasibility of detecting
apoptosis in patients with progressive idiopathic dilated
cardiomyopathy was demonstrated in a proof of principle
study done by Kietselaer [90]. Nine patients with idiopathic
dilated cardiomyopathy (IDCM) were evaluated, as well as
two family members with hypertrophic cardiomyopathy in
different stages of disease. Patients were imaged with
99mTc-labelled Anx A5.
201Tl images were used for
orientation. Other causes of IDCM were excluded using
laboratory testing, echocardiography and coronary angiog-
raphy. It was found that five patients with IDCM showed
focal uptake of radiolabelled Anx A5 and that one patient
showed global uptake in the left ventricle (Fig. 6, left
panel). No enhanced uptake could be visualised in the other
six patients (Fig. 6) and controls. All cases that showed
Fig. 7 SPECT images of
99mTc-labelled Anx A5 in three patients (10,
3 and 4) are demonstrated. a In patient 10, myocardial uptake (as
outlined by solid circles) is clearly seen in all tomographic
orientations and can be differentiated from the left ventricular cavity,
especially in the transaxial slice. b In patient 3, by contrast, no Anx
A5 uptake is observed, and only background activity is seen. c Patient
4 demonstrates Anx A5 activity in the blood pool originating from the
great vessels (GV great cardiac vein, PA pulmonary artery, Ao aorta)
and ventricular contours, but noa c t i v i t yi so b s e r v e di nt h e
myocardium. The scan of patient 10, with myocardial uptake, was
further processed (Fig. 8). RV right ventricle, LV left ventricle.
Adapted by permission from Macmillan Publishers Ltd: Nature
Medicine [42], copyright 2001
Fig. 8 Diffuse myocardial uptake of
99mTc-labelled Anx A5 in
cardiac allograft. Patient 10 underwent Anx A5 imaging 9 months
after orthotopic heart transplantation. SPECT imaging 3 h after
intravenous injection of radiolabelled Anx A5 demonstrated multifo-
cal myocardial uptake of radiotracer. Smoothing of the images and
cardiac SPECT processing in the short axis, vertical long axis and
horizontal long axis revealed myocardial perfusion scan-like images
with diffuse uptake in the whole myocardium, suggesting apoptosis in
the myocardium. Adapted by permission from Macmillan Publishers
Ltd: Nature Medicine [42], copyright 2001
S94 Eur J Nucl Med Mol Imaging (2007) 34:S86–S98Anx A5 uptake in the heart displayed recent onset or recent
worsening of left ventricular function and functional class.
In cases that did not show Anx A5 uptake, LV function and
clinical status remained stable. Kietselaer concluded that
non-invasive imaging using
99mTc-Anx A5 detects apopto-
sis in patients suffering from IDCM, providing further
evidence for the role of apoptosis in the pathogenesis of
IDCM. In addition, Anx A5 imaging identifies high-risk
patients who might benefit from cell death blocking
strategies.
In addition to imaging of apoptosis, the detection of the
molecular substrates of early-stage alterations leading to
HF, such as vascular remodelling in infarcted tissue, is an
emerging technique. Vascular remodelling is associated
with non-contractile scar tissue formation that may contrib-
ute to adverse LV remodelling. However, none of these
molecular techniques has reached the clinical stage yet.
Cardiac allograft rejection
Until 1997, almost 46,300 heart transplantations had been
carried out worldwide [48]. Despite this encouraging
number, only 50% of cardiac transplant recipients will
survive 10 years and almost all will die within 20 years
unless re-transplantation is preformed [19]. One of the
possible complications for patients who have received a
donor heart is transplant rejection. Under the current
medical guidelines, endomyocardial biopsies (EMBs) are
recommended 15–20 times in the first year after transplan-
tation to monitor potential allograft rejection. EMB is an
invasive diagnostic procedure and not without risk of
complications. Allograft rejection is pathologically charac-
terised by perivascular and interstitial mononuclear inflam-
matory cell infiltration associated with myocyte necrosis
and apoptosis [91, 92]. Because the process of apoptosis
can be pharmaceutically manipulated, identifying apoptosis
non-invasively is of critical importance [93].
In a study done by Narula and co-workers [42], 18
patients who had undergone heart transplantation within the
past year were subjected to non-invasive imaging with Anx
A5. Patients received an injected dose of 555–1,110 MBq
(15–30 mCi) of
99mTc-Anx A5 and underwent SPECT
imaging 1 h after injection (Fig. 7). In 13 out of these 18
patients, no myocardial uptake of
99mTc-Anx A5 was
observed. In the remaining five patients, uptake of
99mTc-
Anx A5 in the myocardial region was observed, which was
associated with at least moderate transplant rejection
(Fig. 8), of International Society of Heart and Lung
Transplantation (ISHLT) grade 2/4. Histological analysis
revealed active caspase-3 in EMB specimens. This study
demonstrated the clinical feasibility of detecting cardiac
allograft rejection induced apoptosis, which, after confirm-
ing these findings in larger clinical studies, might lead to a
reduction for the need of EMBs.
Future perspectives
Of all the apoptotic imaging agents, Anx A5 has made the
most successful transition from the test tube to the clinical
arena. Novel imaging modalities like PET/CT and SPECT/
CT are making a significant contribution to the growing
role of molecular imaging. The combination of anatomical
imaging with CT and biological imaging using SPECT or
PET yields a new synergistic imaging modality that
provides detailed information on the molecular (patho)
physiological processes in relation to exact anatomical
orientation.
The next challenge is to assess the incremental clinical
value of molecular imaging and its ability to change patient
management decisions. For this purpose, prospective cohort
studies need to be designed to evaluate the clinical meaning
of molecular imaging scan results in relation to the
progression of the underlying disease. For instance, data
on the association between Anx A5 uptake in plaques in the
carotid arteries and clinical event rate are still lacking. The
availability of such large clinical datasets may allow for
better stratification of patients and therefore more optimal
treatment decisions.
Finally, we and others have found that not only apoptotic
cells but also viable cells are detectable with Anx A5. Our
work on the vulnerable plaque showed that several
processes leading to plaque instability are associated with
PS expression, such as activated macrophages (inflamma-
tion) and aging red blood cells (intra-plaque haemorrhage).
This ability of Anx A5 to visualise exposed PS in different
biological conditions opens novel opportunities for imaging.
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